<DOC>
	<DOCNO>NCT00077389</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Giving chemotherapy drug surgery may shrink tumor remove . PURPOSE : This phase II trial study well neoadjuvant chemotherapy work treat young patient undergoing surgical resection high-risk hepatoblastoma .</brief_summary>
	<brief_title>Intensive Neoadjuvant Chemotherapy Treating Young Patients Undergoing Surgical Resection High-Risk Hepatoblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy short-term toxicity intensify neoadjuvant chemotherapy child high-risk hepatoblastoma undergo surgical resection . - Increase rate complete surgical resection patient fully implement liver transplantation valid treatment option tumor removal partial liver resection surgical option remain unfeasible even extensive preoperative chemotherapy . - Determine , prospectively , role regimen render unresectable tumor resectable patient . - Determine accuracy initial image predict surgical option ( treatment regimen ) patient present unresectable disease . Secondary - Determine overall survival event-free survival patient treat regimen ( acceptable overall toxicity ) . - Determine toxicity regimen patient . - Determine response rate patient treat regimen . - Determine whether response regimen , define modify RECIST criterion , use well monitor response patient . - Determine whether fall alpha-fetoprotein neoadjuvant regimen use prognostic factor patient . - Determine , prospectively , radiological , surgical , pathological characteristic tumor might identify possible novel factor might influence treatment choice outcome patient . OUTLINE : This open-label , multicenter study . - Intensified neoadjuvant chemotherapy : Patients receive cisplatin IV 24 hour day 1 , 8 , 15 , 29 , 36 , 43 , 57 , 64 ; doxorubicin IV 1 hour OR 24 hour day 8 , 9 , 36 , 37 , 57 , 58 . Patients determine resectable disease proceed surgery . Patients determine unresectable disease neoadjuvant chemotherapy receive additional neoadjuvant chemotherapy comprise carboplatin IV 1 hour day 1 22 doxorubicin IV 1 hour OR 24 hour day 1 , 2 , 3 , 22 , 23 , 24 . Treatment continue absence unacceptable toxicity . - Surgery : Patients determine resectable disease undergo complete resection possibly liver transplantation . - Adjuvant chemotherapy* : Patients undergo complete surgical resection receive carboplatin IV 1 hour day 1 doxorubicin IV 1 hour OR 24 hour day 1 2 . Treatment repeat every 3 week total 3 course . NOTE : *Patients receive additional neoadjuvant chemotherapy unresectable disease receive adjuvant chemotherapy . Patients follow every 2-3 month 2 year , every 3 month 1 year , every 6 month 2 year . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 23-57 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Hepatoblastoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm hepatoblastoma Highrisk disease , meet criterion least 1 follow : Tumor involve 4 hepatic section Evidence abdominal extrahepatic disease Presence metastases Alphafetoprotein &lt; 100 ng/mL diagnosis Must prior diagnostic biopsy within past 15 day No recurrent disease PATIENT CHARACTERISTICS : Age Under 18 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic AST and/or ALT ≤ 3 time normal Renal Glomerular filtration rate ≥ 60 mL/min Cardiovascular Shortening fraction ≥ 29 % OR Ejection fraction ≥ 40 % Other Not pregnant Negative pregnancy test No preexisting clinically relevant bilateral hearing loss No condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No prior therapy hepatoblastoma</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>childhood hepatoblastoma</keyword>
	<keyword>stage IV childhood liver cancer</keyword>
</DOC>